News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The AbbVie (ABBV) Culture Change Continues: 100 Scientists Will be Laid Off


5/30/2013 8:12:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Less than a month after AbbVie quietly disclosed that its chief scientific officer is unexpectedly retiring (see this), the drugmaker is now shaking up R&D and layoff approximately 100 scientists from its pain discovery program in neuroscience, according to sources. And an AbbVie spokesman confirmed the move. The R&D changes, which the spokesman says will also involve adding some 90 jobs in such therapeutic categories as dermatology, gastroenterology and renal, is part of a larger transformation that AbbVie is undergoing after being split off earlier this from Abbott Laboratories (ABT). Faced with patent expirations on big-selling cholesterol medicines, the drugmaker is laying off hundreds of sales reps (back story). The TriCor pill, which generated nearly $1.4 billion in sales last year, recently lost patent protection and Niaspan, which notched $976 million in 2012 sales, faces generic rivals in a few months.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive

comments powered by Disqus
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES